Herbs (Global Traditional) · European
Crataegus monogyna (Hawthorn)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Crataegus monogyna contains oligomeric procyanidins and flavonoids that act as ACE inhibitors and calcium channel blockers. Clinical studies show it reduces systolic blood pressure by 6.65 mmHg and supports overall cardiovascular function.
Crataegus monogyna (Hawthorn) is a deciduous shrub or small tree native to Europe, northwestern Africa, and western Asia, belonging to the Rosaceae family. The plant's leaves, flowers, and fruits (haws) serve as the primary source material, with extracts typically prepared using water, ethanol, or phenolic extraction methods.
A meta-analysis of six randomized controlled trials (n=428) demonstrated that Crataegus species extracts significantly reduced systolic blood pressure over 10 weeks to 6 months of treatment. One included trial used 250 mg C. monogyna capsules twice daily for 2 months in first-stage hypertension patients, showing blood pressure reductions alongside sleep improvements. A comprehensive safety review of 23 single-herb and 14 multi-herb clinical studies reported only minor gastrointestinal and cardiac adverse events.
Clinical studies have used 250 mg capsules of C. monogyna extract twice daily (500 mg total) for hypertension management over 2 months. Meta-analysis data suggests treatment periods of 4-6 months may provide stronger effects than shorter durations. Consult a healthcare provider before starting any new supplement.
Crataegus monogyna berries and flowering tops contain a rich profile of bioactive compounds rather than significant macronutrient content, as they are used primarily as medicinal preparations rather than caloric food sources. **Key Bioactive Compounds:** • **Oligomeric proanthocyanidins (OPCs):** 1–3% in berries, up to 2–5% in flowering tops; these are the primary cardioactive constituents responsible for vasodilatory and antioxidant effects; bioavailability is moderate, with absorption estimated at 10–20% in the upper GI tract. • **Flavonoids (total):** 1–2.5% dry weight, including **hyperoside** (quercetin-3-O-galactoside, ~0.3–0.8%), **vitexin** (apigenin-8-C-glucoside, ~0.1–0.5%), **vitexin-2"-O-rhamnoside** (~0.2–0.7%), **rutin** (~0.1–0.3%), and **quercetin** (free aglycone, trace to ~0.05%). Flavonoid glycosides have moderate oral bioavailability (~5–15%) with extensive first-pass metabolism. • **Phenolic acids:** chlorogenic acid (~0.2–0.6%), caffeic acid (trace amounts); contribute to overall antioxidant capacity. • **Triterpenic acids:** ursolic acid (~0.3–0.8%) and oleanolic acid (~0.1–0.4%) found primarily in berries; poorly water-soluble with low oral bioavailability (~1–5%) unless lipid-formulated. • **Vitamin C:** approximately 100–170 mg per 100 g fresh berries (varies by harvest time and cultivar), making them a notable wild source of ascorbic acid. • **Minerals:** potassium (~300–500 mg/100 g dry weight), calcium (~50–80 mg/100 g), magnesium (~30–50 mg/100 g), iron (~1–3 mg/100 g), and trace amounts of zinc and manganese. • **Dietary fiber:** approximately 10–15 g per 100 g dry berries (predominantly insoluble pectin-based fiber). • **Sugars and carbohydrates:** fresh berries contain ~15–25% total sugars (primarily fructose and glucose), with low protein (~1–2 g/100 g fresh weight) and negligible fat (<1 g/100 g). • **Amines:** trace phenylethylamine and tyramine have been reported. • **Carotenoids:** beta-carotene present at approximately 1–5 mg/100 g dry berries, contributing to the red-orange fruit pigmentation. **Standardization notes:** European Pharmacopoeia standardizes hawthorn leaf and flower extracts to contain ≥1.5% flavonoids calculated as hyperoside, or ≥6.0% OPCs for quantified extracts (e.g., WS 1442 standardized to 18.75% OPCs per dose). Most clinical trial evidence uses extracts delivering 160–900 mg extract/day providing approximately 30–170 mg OPCs daily. **Bioavailability considerations:** OPCs and flavonoid glycosides undergo extensive gut microbial metabolism; co-administration with food may enhance absorption of lipophilic triterpenes but may delay peak plasma levels of flavonoids. Aqueous and hydroethanolic preparations show differing extraction efficiencies—ethanol-water (45–70%) extracts yield significantly higher OPC and flavonoid concentrations than simple aqueous infusions.
Hawthorn's oligomeric procyanidins and flavonoids like vitexin inhibit angiotensin-converting enzyme (ACE), reducing vasoconstriction. The compounds also block L-type calcium channels in vascular smooth muscle, promoting vasodilation. Additionally, procyanidins enhance nitric oxide production, further supporting cardiovascular relaxation.
A meta-analysis of 6 randomized controlled trials (n=428) demonstrated that hawthorn supplementation reduces systolic blood pressure by an average of 6.65 mmHg. Studies lasting 4-6 months showed significantly stronger cardiovascular benefits compared to shorter-duration trials. Preliminary evidence suggests hawthorn may improve sleep disorders in hypertensive patients, though this requires further investigation. The evidence base consists primarily of small-scale RCTs with moderate methodological quality.
Hawthorn is generally well-tolerated with mild side effects including dizziness, nausea, and digestive upset in some users. It may potentiate the effects of cardiac medications including digoxin, beta-blockers, and ACE inhibitors, requiring medical supervision. Hawthorn can enhance the hypotensive effects of blood pressure medications, potentially causing excessive blood pressure reduction. Safety during pregnancy and breastfeeding has not been established, so use should be avoided during these periods.
